NCT04817228 - A Study to Evaluate the Clinical Performance, Safety and Pharmacology Effect of EscharEx in Patients With Lower Leg Ulcers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 21, 2021

Primary Completion Date

May 6, 2022

Study Completion Date

May 20, 2022

Conditions

Venous Leg UlcerDiabetic Foot Ulcer

Interventions

DRUG

EscharEx (EX-02 formulation)

EscharEx (EX-02 formulation) gel is topically applied on a wound surface of up to 80 cm2 , up to 8 consecutive applications or until a complete debridement is achieved, whichever occurs first.

Trial Locations (3)

33133

Barry University foot and ankle institute, Tamarac

89119

Clinical Research Medical Center, LLC, Las Vegas

27599-7212

University of North Carolina, Chapel Hill